{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:33:03Z","timestamp":1778067183663,"version":"3.51.4"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1011881","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000}}],"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Antibody-based therapeutics must not undergo chemical modifications that would impair their efficacy or hinder their developability. A commonly used technique to de-risk lead biotherapeutic candidates annotates chemical liability motifs on their sequence. By analyzing sequences from all major sources of data (therapeutics, patents, GenBank, literature, and next-generation sequencing outputs), we find that almost all antibodies contain an average of 3\u20134 such liability motifs in their paratopes, irrespective of the source dataset. This is in line with the common wisdom that liability motif annotation is over-predictive. Therefore, we have compiled three computational flags to prioritize liability motifs for removal from lead drug candidates: 1. germline, to reflect naturally occurring motifs, 2. therapeutic, reflecting chemical liability motifs found in therapeutic antibodies, and 3. surface, indicative of structural accessibility for chemical modification. We show that these flags annotate approximately 60% of liability motifs as benign, that is, the flagged liabilities have a smaller probability of undergoing degradation as benchmarked on two experimental datasets covering deamidation, isomerization, and oxidation. We combined the liability detection and flags into a tool called Liability Antibody Profiler (LAP), publicly available at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/lap.naturalantibody.com\/\" xlink:type=\"simple\">lap.naturalantibody.com<\/jats:ext-link>. We anticipate that LAP will save time and effort in de-risking therapeutic molecules.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1011881","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T18:31:22Z","timestamp":1709663482000},"page":"e1011881","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["LAP: Liability Antibody Profiler by sequence &amp; structural mapping of natural and therapeutic antibodies"],"prefix":"10.1371","volume":"20","author":[{"given":"Tadeusz","family":"Sat\u0142awa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Tarkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Dudzic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Gaw\u0142owski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-2282","authenticated-orcid":true,"given":"Marek","family":"Or\u0142owski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kostyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0697-5522","authenticated-orcid":true,"given":"Konrad","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"pcbi.1011881.ref001","first-page":"233","article-title":"The global landscape of approved antibody therapies.","volume":"5","author":"X Lyu","year":"2022","journal-title":"Antib Ther"},{"key":"pcbi.1011881.ref002","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"T Jain","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1011881.ref003","doi-asserted-by":"crossref","first-page":"2200540","DOI":"10.1080\/19420862.2023.2200540","article-title":"Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches.","volume":"15","author":"T Jain","year":"2023","journal-title":"MAbs"},{"key":"pcbi.1011881.ref004","first-page":"13","article-title":"Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics","volume":"6","author":"W Zhang","year":"2023","journal-title":"Antib Ther"},{"key":"pcbi.1011881.ref005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/mabs.23392","article-title":"Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression.","volume":"5","author":"A Buchanan","year":"2013","journal-title":"MAbs"},{"key":"pcbi.1011881.ref006","doi-asserted-by":"crossref","first-page":"2020082","DOI":"10.1080\/19420862.2021.2020082","article-title":"Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.","volume":"14","author":"R Khetan","year":"2022","journal-title":"MAbs"},{"key":"pcbi.1011881.ref007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/19420862.2018.1548233","article-title":"Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.","volume":"11","author":"X Lu","year":"2019","journal-title":"MAbs"},{"key":"pcbi.1011881.ref008","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1073\/pnas.1810576116","article-title":"Five computational developability guidelines for therapeutic antibody profiling","volume":"116","author":"MIJ Raybould","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1011881.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41120-022-00057-2","article-title":"Utilizing cross-product prior knowledge to rapidly de-risk chemical liabilities in therapeutic antibody candidates.","volume":"8","author":"AW Jacobitz","year":"2022","journal-title":"AAPS Open"},{"key":"pcbi.1011881.ref010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2009.04.007","article-title":"Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action","volume":"30","author":"R. Jefferis","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"pcbi.1011881.ref011","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/ac0494174","article-title":"In vivo deamidation characterization of monoclonal antibody by LC\/MS\/MS","volume":"77","author":"L Huang","year":"2005","journal-title":"Anal Chem"},{"key":"pcbi.1011881.ref012","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1021\/bi951526c","article-title":"Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity","volume":"35","author":"J Cacia","year":"1996","journal-title":"Biochemistry"},{"key":"pcbi.1011881.ref013","doi-asserted-by":"crossref","first-page":"2143006","DOI":"10.1080\/19420862.2022.2143006","article-title":"Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue","volume":"14","author":"FJ Irudayanathan","year":"2022","journal-title":"MAbs"},{"key":"pcbi.1011881.ref014","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.omtm.2019.09.008","article-title":"Machine Learning Enables Accurate Prediction of Asparagine Deamidation Probability and Rate","volume":"15","author":"JA Delmar","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"pcbi.1011881.ref015","doi-asserted-by":"crossref","first-page":"e0181347","DOI":"10.1371\/journal.pone.0181347","article-title":"Protein asparagine deamidation prediction based on structures with machine learning methods.","volume":"12","author":"L Jia","year":"2017","journal-title":"PLoS One"},{"key":"pcbi.1011881.ref016","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1021\/acs.molpharmaceut.8b01311","article-title":"Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner","volume":"16","author":"ME Alam","year":"2019","journal-title":"Mol Pharm"},{"key":"pcbi.1011881.ref017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/mabs.3.3.15608","article-title":"Fragmentation of monoclonal antibodies.","volume":"3","author":"J Vlasak","year":"2011","journal-title":"MAbs"},{"key":"pcbi.1011881.ref018","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/acs.analchem.5b02800","article-title":"Isomerization and Oxidation in the Complementarity-Determining Regions of a Monoclonal Antibody: A Study of the Modification-Structure-Function Correlations by Hydrogen-Deuterium Exchange Mass Spectrometry","volume":"88","author":"Y Yan","year":"2016","journal-title":"Anal Chem"},{"key":"pcbi.1011881.ref019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/jmbi.1996.0726","article-title":"A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding","volume":"265","author":"K Proba","year":"1997","journal-title":"J Mol Biol"},{"key":"pcbi.1011881.ref020","doi-asserted-by":"crossref","first-page":"107831","DOI":"10.1016\/j.celrep.2020.107831","article-title":"Landscape of Non-canonical Cysteines in Human VH Repertoire Revealed by Immunogenetic Analysis","volume":"31","author":"P Prabakaran","year":"2020","journal-title":"Cell Rep"},{"key":"pcbi.1011881.ref021","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00253-020-10368-7","article-title":"Antibody glycosylation: impact on antibody drug characteristics and quality control","volume":"104","author":"Z Wang","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"pcbi.1011881.ref022","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.xphs.2020.10.039","article-title":"Tryptophan Oxidation of a Monoclonal Antibody Under Diverse Oxidative Stress Conditions: Distinct Oxidative Pathways Favor Specific Tryptophan Residues","volume":"110","author":"AW Jacobitz","year":"2021","journal-title":"J Pharm Sci"},{"key":"pcbi.1011881.ref023","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/713803735","article-title":"Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulation","volume":"50","author":"RL Levine","year":"2000","journal-title":"IUBMB Life"},{"key":"pcbi.1011881.ref024","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"RO Hynes","year":"2002","journal-title":"Cell"},{"key":"pcbi.1011881.ref025","doi-asserted-by":"crossref","first-page":"1892366","DOI":"10.1080\/19420862.2021.1892366","article-title":"Data mining patented antibody sequences.","volume":"13","author":"K Krawczyk","year":"2021","journal-title":"MAbs"},{"key":"pcbi.1011881.ref026","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/bioinformatics\/btac151","article-title":"AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design","volume":"38","author":"J M\u0142okosiewicz","year":"2022","journal-title":"Bioinformatics"},{"key":"pcbi.1011881.ref027","doi-asserted-by":"crossref","first-page":"D67","DOI":"10.1093\/nar\/gkv1276","article-title":"GenBank.","volume":"44","author":"K Clark","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1011881.ref028","doi-asserted-by":"crossref","first-page":"D261","DOI":"10.1093\/nar\/gkz714","article-title":"The ABCD database: a repository for chemically defined antibodies","volume":"48","author":"WC Lima","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1011881.ref029","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41586-022-05371-z","article-title":"Functional antibodies exhibit light chain coherence","volume":"611","author":"DB Jaffe","year":"2022","journal-title":"Nature"},{"key":"pcbi.1011881.ref030","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2018.02278","article-title":"Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface\/Residue Definition.","volume":"9","author":"M Dondelinger","year":"2018","journal-title":"Front Immunol."},{"key":"pcbi.1011881.ref031","volume-title":"Proteins: structures and molecular properties.","author":"TE Creighton","year":"1993"},{"key":"pcbi.1011881.ref032","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac267","article-title":"Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery","volume":"23","author":"W Wilman","year":"2022","journal-title":"Brief Bioinform"},{"key":"pcbi.1011881.ref033","first-page":"2022","article-title":"Structural pre-training improves physical accuracy of antibody structure prediction using deep learning","author":"J Ko\u0144czak","year":"2022","journal-title":"bioRxiv"},{"key":"pcbi.1011881.ref034","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s42003-023-04927-7","article-title":"ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins","volume":"6","author":"B Abanades","year":"2023","journal-title":"Commun Biol"},{"key":"pcbi.1011881.ref035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/19420862.2017.1290753","article-title":"Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies.","volume":"9","author":"R Yang","year":"2017","journal-title":"MAbs"},{"key":"pcbi.1011881.ref036","doi-asserted-by":"crossref","first-page":"2115200","DOI":"10.1080\/19420862.2022.2115200","article-title":"Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs.","volume":"14","author":"AAR Teixeira","year":"2022","journal-title":"MAbs"},{"key":"pcbi.1011881.ref037","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.1021\/acs.analchem.5b02385","article-title":"Characterization of the acidic species of a monoclonal antibody using weak cation exchange chromatography and LC-MS","volume":"87","author":"G Ponniah","year":"2015","journal-title":"Anal Chem"},{"key":"pcbi.1011881.ref038","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.analchem.6b04158","article-title":"Rate of Asparagine Deamidation in a Monoclonal Antibody Correlating with Hydrogen Exchange Rate at Adjacent Downstream Residues","volume":"89","author":"JJ Phillips","year":"2017","journal-title":"Anal Chem"},{"key":"pcbi.1011881.ref039","doi-asserted-by":"crossref","first-page":"1980942","DOI":"10.1080\/19420862.2021.1980942","article-title":"Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.","volume":"13","author":"A Azevedo Reis Teixeira","year":"2021","journal-title":"MAbs"},{"key":"pcbi.1011881.ref040","article-title":"Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups.","author":"BN Rome","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"pcbi.1011881.ref041","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.4049\/jimmunol.1800708","article-title":"Observed Antibody Space: A Resource for Data Mining Next-Generation Sequencing of Antibody Repertoires","volume":"201","author":"A Kovaltsuk","year":"2018","journal-title":"J Immunol"},{"key":"pcbi.1011881.ref042","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pro.4205","article-title":"Observed Antibody Space: A diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences","volume":"31","author":"TH Olsen","year":"2022","journal-title":"Protein Sci"},{"key":"pcbi.1011881.ref043","article-title":"Building Representation Learning Models for Antibody Comprehension.","author":"J Barton","year":"2023","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"pcbi.1011881.ref044","doi-asserted-by":"crossref","first-page":"D1273","DOI":"10.1093\/nar\/gkab1021","article-title":"INDI\u2014integrated nanobody database for immunoinformatics","volume":"50","author":"P Deszy\u0144ski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1011881.ref045","doi-asserted-by":"crossref","DOI":"10.3109\/9780849379529","volume-title":"Protein Formulation and Delivery","author":"EJ McNally","year":"2007","edition":"2"},{"key":"pcbi.1011881.ref046","volume-title":"Developability of Biotherapeutics.","author":"S Kumar","year":"2021"},{"key":"pcbi.1011881.ref047","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/bioinformatics\/btv552","article-title":"ANARCI: antigen receptor numbering and receptor classification","volume":"32","author":"J Dunbar","year":"2016","journal-title":"Bioinformatics"},{"key":"pcbi.1011881.ref048","doi-asserted-by":"crossref","first-page":"D1051","DOI":"10.1093\/nar\/gkz872","article-title":"VDJbase: an adaptive immune receptor genotype and haplotype database","volume":"48","author":"A Omer","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1011881.ref049","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/bioinformatics\/btz845","article-title":"Benchmarking immunoinformatic tools for the analysis of antibody repertoire sequences","volume":"36","author":"E Smakaj","year":"2020","journal-title":"Bioinformatics"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1011881","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:04:12Z","timestamp":1711044252000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011881"}},"subtitle":[],"editor":[{"given":"Nir","family":"Ben-Tal","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1011881","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1011881","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}